254 related articles for article (PubMed ID: 29959604)
1. Risk of diabetes complications among those with diabetes receiving androgen deprivation therapy for localized prostate cancer.
Bradley MC; Zhou Y; Freedman AN; Yood MU; Quesenbery CP; Haque R; Van Den Eeden SK; Cassidy-Bushrow AE; Aaronson D; Potosky AL
Cancer Causes Control; 2018 Aug; 29(8):785-791. PubMed ID: 29959604
[TBL] [Abstract][Full Text] [Related]
2. Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer.
Crawley D; Garmo H; Rudman S; Stattin P; Häggström C; Zethelius B; Holmberg L; Adolfsson J; Van Hemelrijck M
Int J Cancer; 2016 Dec; 139(12):2698-2704. PubMed ID: 27557616
[TBL] [Abstract][Full Text] [Related]
3. New-onset diabetes after androgen-deprivation therapy for prostate cancer: A nationwide propensity score-matched four-year longitudinal cohort study.
Jhan JH; Yeh HC; Chang YH; Guu SJ; Wu WJ; Chou YH; Li CC
J Diabetes Complications; 2018 Jul; 32(7):688-692. PubMed ID: 29909141
[TBL] [Abstract][Full Text] [Related]
4. Risks of Major Long-Term Side Effects Associated with Androgen-Deprivation Therapy in Men with Prostate Cancer.
Nguyen C; Lairson DR; Swartz MD; Du XL
Pharmacotherapy; 2018 Oct; 38(10):999-1009. PubMed ID: 30080934
[TBL] [Abstract][Full Text] [Related]
5. Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications.
Shao YH; Moore DF; Shih W; Lin Y; Jang TL; Lu-Yao GL
BJU Int; 2013 May; 111(5):745-52. PubMed ID: 23331464
[TBL] [Abstract][Full Text] [Related]
6. Androgen deprivation therapy, diabetes and poor physical performance status increase fracture risk in Chinese men treated for prostate cancer.
Teoh JY; Chiu PK; Chan SY; Poon DM; Cheung HY; Hou SS; Ng CF
Aging Male; 2015; 18(3):180-5. PubMed ID: 26004988
[TBL] [Abstract][Full Text] [Related]
7. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.
Kintzel PE; Chase SL; Schultz LM; O'Rourke TJ
Pharmacotherapy; 2008 Dec; 28(12):1511-22. PubMed ID: 19025432
[TBL] [Abstract][Full Text] [Related]
8. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
[TBL] [Abstract][Full Text] [Related]
9. Retrospective cohort study of androgen deprivation therapy and the risk of diabetes in men with prostate cancer in Lithuania.
Drevinskaite M; Patasius A; Kincius M; Urbonas V; Smailyte G
BMJ Open; 2021 Jul; 11(7):e045797. PubMed ID: 34321292
[TBL] [Abstract][Full Text] [Related]
10. Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series.
Gandaglia G; Fossati N; Karnes RJ; Boorjian SA; Colicchia M; Bossi A; Seisen T; Cozzarini C; Di Muzio N; Noris Chiorda B; Zaffuto E; Wiegel T; Shariat SF; Goldner G; Joniau S; Battaglia A; Haustermans K; De Meerleer G; Fonteyne V; Ost P; Van Poppel H; Montorsi F; Briganti A
Eur Urol; 2018 Apr; 73(4):512-518. PubMed ID: 29229176
[TBL] [Abstract][Full Text] [Related]
11. Association Between Androgen Deprivation Therapy Use and Diagnosis of Dementia in Men With Prostate Cancer.
Jayadevappa R; Chhatre S; Malkowicz SB; Parikh RB; Guzzo T; Wein AJ
JAMA Netw Open; 2019 Jul; 2(7):e196562. PubMed ID: 31268539
[TBL] [Abstract][Full Text] [Related]
12. Statin reduces the risk of dementia in diabetic patients receiving androgen deprivation therapy for prostate cancer.
Liu JM; Chen TH; Chuang HC; Wu CT; Hsu RJ
Prostate Cancer Prostatic Dis; 2019 May; 22(2):276-283. PubMed ID: 30337635
[TBL] [Abstract][Full Text] [Related]
13. Association between ischaemic bowel syndromes and androgen deprivation therapy in patients with prostate cancer: a retrospective cohort study.
Chiang IN; Huang CY; Pu YS; Chang CH; Muo CH; Chung CJ; Wang RY; Young TH
BMJ Open; 2017 Feb; 7(2):e012950. PubMed ID: 28246133
[TBL] [Abstract][Full Text] [Related]
14. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR
J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537
[TBL] [Abstract][Full Text] [Related]
15. Association between androgen-deprivation therapy and incidence of diabetes among males with prostate cancer.
Lage MJ; Barber BL; Markus RA
Urology; 2007 Dec; 70(6):1104-8. PubMed ID: 18158027
[TBL] [Abstract][Full Text] [Related]
16. No increased risk of coronary heart disease for patients receiving androgen deprivation therapy for prostate cancer in Chinese/Taiwanese men.
Wang LH; Liu CK; Chen CH; Kao LT; Lin HC; Huang CY
Andrology; 2016 Jan; 4(1):128-32. PubMed ID: 26711703
[TBL] [Abstract][Full Text] [Related]
17. Risk of acute myocardial infarction after androgen-deprivation therapy for prostate cancer in a Chinese population.
Teoh JY; Chan SY; Chiu PK; Poon DM; Cheung HY; Hou SS; Ng CF
BJU Int; 2015 Sep; 116(3):382-7. PubMed ID: 25327618
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the effectiveness of adding androgen deprivation to modern dose-escalated radiotherapy for men with favorable intermediate-risk prostate cancer.
Falchook AD; Basak R; Mohiuddin JJ; Chen RC
Cancer; 2016 Aug; 122(15):2341-9. PubMed ID: 27191936
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular and Skeletal-related Events Following Localized Prostate Cancer Treatment: Role of Surgery, Radiotherapy, and Androgen Deprivation.
Wallis CJ; Mahar AL; Satkunasivam R; Herschorn S; Kodama RT; Lee Y; Kulkarni GS; Narod SA; Nam RK
Urology; 2016 Nov; 97():145-152. PubMed ID: 27502032
[TBL] [Abstract][Full Text] [Related]
20. Androgen deprivation therapy for treatment of localized prostate cancer and risk of second primary malignancies.
Wallner LP; Wang R; Jacobsen SJ; Haque R
Cancer Epidemiol Biomarkers Prev; 2013 Feb; 22(2):313-6. PubMed ID: 23292083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
